Menu Search
Equities

Akoya Biosciences Inc

AKYA:NSQ

Akoya Biosciences Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)3.17
  • Today's Change-0.05 / -1.55%
  • Shares traded59.09k
  • 1 Year change-15.69%
  • Beta1.3882
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Akoya Biosciences Inc grew revenues 29.09% from 74.86m to 96.63m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -70.64m to -63.32m.
Gross margin57.57%
Net profit margin-64.74%
Operating margin-57.56%
Return on assets-36.29%
Return on equity-128.20%
Return on investment-45.98%
More ▼

Cash flow in USDView more

In 2023, Akoya Biosciences Inc increased its cash reserves by 12.47%, or 9.29m. Cash Flow from Financing totalled 56.84m or 58.82% of revenues. In addition the company used 50.90m for operations while cash from investing totalled 3.35m.
Cash flow per share-1.05
Price/Cash flow per share--
Book value per share0.4498
Tangible book value per share-0.2426
More ▼

Balance sheet in USDView more

Akoya Biosciences Inc has a Debt to Total Capital ratio of 77.55%, a lower figure than the previous year's 89.99%.
Current ratio2.73
Quick ratio1.98
Total debt/total equity3.45
Total debt/total capital0.7755
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.